Mark Daniel  Fleming

Mark Daniel Fleming, MD, DPhil


S. Burt Wolbach Professor of Pathology, Harvard Medical School

  • Contact: 617-919-2664

  • Fax: 617-730-0168

Medical Services


  • Iron Metabolism
  • Sideroblastic Anemia
  • Hematopathology


  • Pathology


  • Lymphoma Program
  • Myelodysplastic Syndrome Specialty Program
  • Leukemia
  • Hematopathology
To schedule an appointment: Call 617-919-2664

Experience and Education


Undergraduate Degree, A.B. in Molecular Biology

Princeton University, 1987

Princeton, NJ

Graduate Degree, D. Phil. in Organic Chemistry

University of Oxford, 1990

Oxford, England

Medical School

Harvard Medical School, 1993

Boston, MA


Brigham and Women's Hospital, 1993-1995

Boston, MA

Residency, Anatomic Pathology

Brigham and Women's Hospital, 07/94 to 06/95

Boston, MA

Senior Resident in Surgical Pathology

Brigham and Women's Hospital, 1996

Boston, MA

Fellowship, Hematopathology

Brigham and Women's Hospital, 7/1995-12/1996

Boston, MA

Postdoctoral Fellow in Hematology/Oncology

Boston Children's Hospital, 1997-2000

Boston, MA


  • Anatomic Pathology and Hematopathology


Research interests include: Molecular genetics of erythroid iron metabolism

Mark D. Fleming, MD, DPhil PubMed articles


Publications powered by Harvard Catalyst Profiles
  1. Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, Schneider RK, Lord AM, Wang L, Gambe RG, McConkey ME, Ali AM, Raza A, Yu L, Buonamici S, Smith PG, Mullally A, Wu CJ, Fleming MD, Ebert BL. Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation. Cancer Cell. 2016 Sep 12; 30(3):404-17.
  2. Heideman PP, Rajebi MR, McKusick MA, Bjarnason H, Oderich GS, Friese JL, Fleming MD, Stockland AH, Harmsen WS, Mandrekar J, Misra S. Impact of Chronic Kidney Disease on Clinical Outcomes of Endovascular Treatment for Femoropopliteal Arterial Disease. J Vasc Interv Radiol. 2016 Aug; 27(8):1204-14.
  3. Gifford SM, Fleming MD, Mendes BC, Stauffer KC, De Martino RR, Oderich GS, Gloviczki P, Bower TC. Impact of femoropopliteal endovascular interventions on subsequent open bypass. J Vasc Surg. 2016 Sep; 64(3):623-8.
  4. Cao C, Fleming MD. The placenta: the forgotten essential organ of iron transport. Nutr Rev. 2016 Jul; 74(7):421-31.
  5. Mangum JE, Hardee JP, Fix DK, Puppa MJ, Elkes J, Altomare D, Bykhovskaya Y, Campagna DR, Schmidt PJ, Sendamarai AK, Lidov HG, Barlow SC, Fischel-Ghodsian N, Fleming MD, Carson JA, Patton JR. Pseudouridine synthase 1 deficient mice, a model for Mitochondrial Myopathy with Sideroblastic Anemia, exhibit muscle morphology and physiology alterations. Sci Rep. 2016; 6:26202.
  6. Peeran S, DeMartino RR, Huang Y, Fleming M, Kalra M, Oderich GS, Duncan AA, Bower TC, Gloviczki P. Outcomes of Women Treated for Popliteal Artery Aneurysms. Ann Vasc Surg. 2016 Jul; 34:187-92.
  7. Guo W, Schmidt PJ, Fleming MD, Bhasin S. Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation. Endocrinology. 2016 Jul; 157(7):2937-46.
  8. Gifford SM, Duncan AA, Greiten LE, Gloviczki P, Oderich GS, Kalra M, Fleming MD, Bower TC. The natural history and outcomes for thoracic and abdominal penetrating aortic ulcers. J Vasc Surg. 2016 May; 63(5):1182-8.
  9. Jabara HH, Boyden SE, Chou J, Ramesh N, Massaad MJ, Benson H, Bainter W, Fraulino D, Rahimov F, Sieff C, Liu ZJ, Alshemmari SH, Al-Ramadi BK, Al-Dhekri H, Arnaout R, Abu-Shukair M, Vatsayan A, Silver E, Ahuja S, Davies EG, Sola-Visner M, Ohsumi TK, Andrews NC, Notarangelo LD, Fleming MD, Al-Herz W, Kunkel LM, Geha RS. A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency. Nat Genet. 2016 Jan; 48(1):74-8.
  10. Latour C, Besson-Fournier C, Meynard D, Silvestri L, Gourbeyre O, Aguilar-Martinez P, Schmidt PJ, Fleming MD, Roth MP, Coppin H. Differing impact of the deletion of hemochromatosis-associated molecules HFE and transferrin receptor-2 on the iron phenotype of mice lacking bone morphogenetic protein 6 or hemojuvelin. Hepatology. 2016 Jan; 63(1):126-37.
  11. Show all
  12. Fleming MD, Pockaj BA, Hansen AJ, Gray RJ, Patel MD. Radioactive seed localization for excision of non-palpable in-transit metastatic melanoma. Radiol Case Rep. 2006; 1(2):54-7.
  13. Schmitz-Abe K, Ciesielski SJ, Schmidt PJ, Campagna DR, Rahimov F, Schilke BA, Cuijpers M, Rieneck K, Lausen B, Linenberger ML, Sendamarai AK, Guo C, Hofmann I, Newburger PE, Matthews D, Shimamura A, Snijders PJ, Towne MC, Niemeyer CM, Watson HG, Dziegiel MH, Heeney MM, May A, Bottomley SS, Swinkels DW, Markianos K, Craig EA, Fleming MD. Congenital sideroblastic anemia due to mutations in the mitochondrial HSP70 homologue HSPA9. Blood. 2015 Dec 17; 126(25):2734-8.
  14. Strajina V, Oderich GS, Fatima J, Gloviczki P, Duncan AA, Kalra M, Fleming M, Macedo TA. Endovascular aortic aneurysm repair in patients with narrow aortas using bifurcated stent grafts is safe and effective. J Vasc Surg. 2015 Nov; 62(5):1140-7.e1.
  15. Reed NR, Oderich GS, Manunga J, Duncan A, Misra S, de Souza LR, Fleming M, de Martino R. Feasibility of endovascular repair of splenic artery aneurysms using stent grafts. J Vasc Surg. 2015 Dec; 62(6):1504-10.
  16. Herrmann J, Bell MR, Warren RL, Lerman A, Fleming MD, Patnaik M. Complicated and Advanced Atherosclerosis in a Young Woman With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Success and Challenges of BCR/ABL1-Targeted Cancer Therapy. Mayo Clin Proc. 2015 Aug; 90(8):1167-8.
  17. Cao C, Fleming MD. The ins and outs of erythroid heme transport. Haematologica. 2015 Jun; 100(6):703.
  18. Johnstone JK, Fleming MD, Gloviczki P, Stone W, Kalra M, Oderich GS, Duncan AA, De Martino RR, Bower TC. Surgical treatment of popliteal venous aneurysms. Ann Vasc Surg. 2015 Aug; 29(6):1084-9.
  19. Scott A, Glover J, Skoda-Smith S, Torgerson TR, Xu M, Burroughs LM, Woolfrey AE, Fleming MD, Shimamura A. Severe combined immunodeficiency (SCID) presenting with neonatal aplastic anemia. Pediatr Blood Cancer. 2015 Nov; 62(11):2047-9.
  20. Huang Y, Gloviczki P, Oderich GS, Duncan AA, Kalra M, Fleming MD, Harmsen WS, Bower TC. Outcome after open and endovascular repairs of abdominal aortic aneurysms in matched cohorts using propensity score modeling. J Vasc Surg. 2015 Aug; 62(2):304-11.e2.
  21. Schmidt PJ, Racie T, Westerman M, Fitzgerald K, Butler JS, Fleming MD. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of ß-thalassemia intermedia. Am J Hematol. 2015 Apr; 90(4):310-3.
  22. Rana MA, Gloviczki P, Kalra M, Bjarnason H, Huang Y, Fleming MD. Open surgical removal of retained and dislodged inferior vena cava filters. J Vasc Surg Venous Lymphat Disord. 2015 Apr; 3(2):201-6.
  23. Fleming MD, Lall P, Nagorney DM, Gloviczki P, Kalra M, Duncan A, Oderich G, Toomey B, Bower TC. Operative interventions for extrahepatic portomesenteric venous aneurysms and long-term outcomes. Ann Vasc Surg. 2015; 29(4):654-60.
  24. Forester CM, Sartain SE, Guo D, Harris MH, Weinberg OK, Fleming MD, London WB, Williams DA, Hofmann I. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. Am J Hematol. 2015 Apr; 90(4):320-6.
  25. Sabino J, Polfer E, Tintle S, Jessie E, Fleming M, Martin B, Shashikant M, Valerio IL. A decade of conflict: flap coverage options and outcomes in traumatic war-related extremity reconstruction. Plast Reconstr Surg. 2015 Mar; 135(3):895-902.
  26. Ludwig LS, Cho H, Wakabayashi A, Eng JC, Ulirsch JC, Fleming MD, Lodish HF, Sankaran VG. Genome-wide association study follow-up identifies cyclin A2 as a regulator of the transition through cytokinesis during terminal erythropoiesis. Am J Hematol. 2015 May; 90(5):386-91.
  27. Rathkolb B, Klempt M, Sabrautzki S, Michel D, Klaften M, Laufs J, Sedlmeier R, Hans W, Fuchs H, Muckenthaler MU, Horsch M, Campagna DR, Fleming M, Hrabé de Angelis M, Wolf E, Aigner B. Screen for alterations of iron related parameters in N-ethyl-N-nitrosourea-treated mice identified mutant lines with increased plasma ferritin levels. Biometals. 2015 Apr; 28(2):293-306.
  28. Gloviczki P, Huang Y, Oderich GS, Duncan AA, Kalra M, Fleming MD, Harmsen WS, Bower TC. Clinical presentation, comorbidities, and age but not female gender predict survival after endovascular repair of abdominal aortic aneurysm. J Vasc Surg. 2015 Apr; 61(4):853-61.e2.
  29. Valerio IL, Campbell P, Sabino J, Dearth CL, Fleming M. The use of urinary bladder matrix in the treatment of trauma and combat casualty wound care. Regen Med. 2015; 10(5):611-22.
  30. Gutschow P, Schmidt PJ, Han H, Ostland V, Bartnikas TB, Pettiglio MA, Herrera C, Butler JS, Nemeth E, Ganz T, Fleming MD, Westerman M. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. Haematologica. 2015 Feb; 100(2):167-77.
  31. Zhang MY, Keel SB, Walsh T, Lee MK, Gulsuner S, Watts AC, Pritchard CC, Salipante SJ, Jeng MR, Hofmann I, Williams DA, Fleming MD, Abkowitz JL, King MC, Shimamura A. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. Haematologica. 2015 Jan; 100(1):42-8.
  32. Chakraborty PK, Schmitz-Abe K, Kennedy EK, Mamady H, Naas T, Durie D, Campagna DR, Lau A, Sendamarai AK, Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Wynn RF, Laxer RM, Minniti CP, Moppett J, Bordon V, Geraghty M, Joyce PB, Markianos K, Rudner AD, Holcik M, Fleming MD. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014 Oct 30; 124(18):2867-71.
  33. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, Suñol M, McKenna A, Sivachenko A, Cibulskis K, Lawrence MS, Stojanov P, Rosenberg M, Ambrogio L, Auclair D, Seepo S, Blumenstiel B, DeFelice M, Imaz-Rosshandler I, Schwarz-Cruz Y Celis A, Rivera MN, Rodriguez-Galindo C, Fleming MD, Golub TR, Getz G, Mora J, Stegmaier K. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov; 4(11):1326-41.
  34. Ohgami RS, Sendamarai AK, Atwater SK, Liedtke M, Fleming MD, Natkunam Y, Warnke RA. Indolent T-lymphoblastic proliferation with disseminated multinodal involvement and partial CD33 expression. Am J Surg Pathol. 2014 Sep; 38(9):1298-304.
  35. Valerio I, Sabino J, Thomas S, Tintle S, Fleming M, Shashikant M, Kumar A. Multiple limbs salvaged using tissue transfers in the same casualty: a cohort comparison study chronicling a decade of war-injured patients. Plast Reconstr Surg. 2014 Aug; 134(2):333-8.
  36. Archer NM, Shmukler BE, Andolfo I, Vandorpe DH, Gnanasambandam R, Higgins JM, Rivera A, Fleming MD, Sachs F, Gottlieb PA, Iolascon A, Brugnara C, Alper SL, Nathan DG. Hereditary xerocytosis revisited. Am J Hematol. 2014 Dec; 89(12):1142-6.
  37. Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am. 2014 Aug; 28(4):653-70, v.
  38. Gifford SM, Kalra M, Gloviczki P, Duncan AA, Oderich GS, Fleming MD, Harmsen S, Bower TC. Reflux in the below-knee great saphenous vein can be safely treated with endovenous ablation. J Vasc Surg Venous Lymphat Disord. 2014 Oct; 2(4):397-402.
  39. Huang Y, Gloviczki P, Oderich GS, Duncan AA, Kalra M, Fleming MD, Harmsen WS, Bower TC. Outcomes of endovascular and contemporary open surgical repairs of popliteal artery aneurysm. J Vasc Surg. 2014 Sep; 60(3):631-8.e2.
  40. Gagne KE, Ghazvinian R, Yuan D, Zon RL, Storm K, Mazur-Popinska M, Andolina L, Bubala H, Golebiowska S, Higman MA, Kalwak K, Kurre P, Matysiak M, Niewiadomska E, Pels S, Petruzzi MJ, Pobudejska-Pieniazek A, Szczepanski T, Fleming MD, Gazda HT, Agarwal S. Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia. Blood. 2014 Jul 17; 124(3):437-40.
  41. Mendes BC, Oderich GS, Fleming MD, Misra S, Duncan AA, Kalra M, Cha S, Gloviczki P. Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices. J Vasc Surg. 2014 Feb; 59(2):359-367.e1.
  42. Schmidt PJ, Fleming MD. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Hematol Oncol Clin North Am. 2014 Apr; 28(2):387-401.
  43. Bishop A, Fleming M. Patient safety and engagement at the frontlines of healthcare. Healthc Q. 2014; 17 Spec No:36-40.
  44. Campagna DR, de Bie CI, Schmitz-Abe K, Sweeney M, Sendamarai AK, Schmidt PJ, Heeney MM, Yntema HG, Kannengiesser C, Grandchamp B, Niemeyer CM, Knoers NV, Swart S, Marron G, van Wijk R, Raymakers RA, May A, Markianos K, Bottomley SS, Swinkels DW, Fleming MD. X-linked sideroblastic anemia due to ALAS2 intron 1 enhancer element GATA-binding site mutations. Am J Hematol. 2014 Mar; 89(3):315-9.
  45. Valerio IL, Sabino J, Bevevino A, Tintle SM, Fleming M, Kumar A. Sequential free tissue transfers for simultaneous upper and lower limb salvage. Microsurgery. 2013 Sep; 33(6):447-53.
  46. Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 1; 119(19):3555-62.
  47. Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):397-406.
  48. Manunga JM, Gloviczki P, Oderich GS, Kalra M, Duncan AA, Fleming MD, Bower TC. Femoral artery calcification as a determinant of success for percutaneous access for endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2013 Nov; 58(5):1208-12.
  49. Cherry AB, Gagne KE, McLoughlin EM, Baccei A, Gorman B, Hartung O, Miller JD, Zhang J, Zon RL, Ince TA, Neufeld EJ, Lerou PH, Fleming MD, Daley GQ, Agarwal S. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013 Jul; 31(7):1287-97.
  50. Johnstone JK, Fleming MD, Costopoulos MG, Bjarnason H. Percutaneous removal of a Bard Simon nitinol permanent inferior vena cava filter. Perspect Vasc Surg Endovasc Ther. 2012 Dec; 24(4):198-201.
  51. Valerio I, Sabino J, Heckert R, Thomas S, Tintle S, Fleming M, Kumar A. Known preoperative deep venous thrombosis and/or pulmonary embolus: to flap or not to flap the severely injured extremity? Plast Reconstr Surg. 2013 Jul; 132(1):213-20.
  52. Gauss GH, Kleven MD, Sendamarai AK, Fleming MD, Lawrence CM. The crystal structure of six-transmembrane epithelial antigen of the prostate 4 (Steap4), a ferri/cuprireductase, suggests a novel interdomain flavin-binding site. J Biol Chem. 2013 Jul 12; 288(28):20668-82.
  53. Wiseman DH, May A, Jolles S, Connor P, Powell C, Heeney MM, Giardina PJ, Klaassen RJ, Chakraborty P, Geraghty MT, Major-Cook N, Kannengiesser C, Thuret I, Thompson AA, Marques L, Hughes S, Bonney DK, Bottomley SS, Fleming MD, Wynn RF. A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Blood. 2013 Jul 4; 122(1):112-23.
  54. Bartnikas TB, Wildt SJ, Wineinger AE, Schmitz-Abe K, Markianos K, Cooper DM, Fleming MD. A novel rat model of hereditary hemochromatosis due to a mutation in transferrin receptor 2. Comp Med. 2013 Apr; 63(2):143-55.
  55. Crompton BD, Carlton AL, Thorner AR, Christie AL, Du J, Calicchio ML, Rivera MN, Fleming MD, Kohl NE, Kung AL, Stegmaier K. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1; 73(9):2873-83.
  56. Yuan X, Fleming MD, Hamza I. Heme transport and erythropoiesis. Curr Opin Chem Biol. 2013 Apr; 17(2):204-11.
  57. White C, Yuan X, Schmidt PJ, Bresciani E, Samuel TK, Campagna D, Hall C, Bishop K, Calicchio ML, Lapierre A, Ward DM, Liu P, Fleming MD, Hamza I. HRG1 is essential for heme transport from the phagolysosome of macrophages during erythrophagocytosis. Cell Metab. 2013 Feb 5; 17(2):261-70.
  58. Anderson SA, Nizzi CP, Chang YI, Deck KM, Schmidt PJ, Galy B, Damnernsawad A, Broman AT, Kendziorski C, Hentze MW, Fleming MD, Zhang J, Eisenstein RS. The IRP1-HIF-2a axis coordinates iron and oxygen sensing with erythropoiesis and iron absorption. Cell Metab. 2013 Feb 5; 17(2):282-90.
  59. Bartnikas TB, Steinbicker AU, Campagna DR, Blevins S, Woodward LS, Herrera C, Bloch KD, Justice MJ, Fleming MD. Identification and characterization of a novel murine allele of Tmprss6. Haematologica. 2013 Jun; 98(6):854-61.
  60. Schmidt PJ, Toudjarska I, Sendamarai AK, Racie T, Milstein S, Bettencourt BR, Hettinger J, Bumcrot D, Fleming MD. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine ß-thalassemia intermedia. Blood. 2013 Feb 14; 121(7):1200-8.
  61. Fleming MD, Hamza I. Mitochondrial heme: an exit strategy at last. J Clin Invest. 2012 Dec; 122(12):4328-30.
  62. Shah DI, Takahashi-Makise N, Cooney JD, Li L, Schultz IJ, Pierce EL, Narla A, Seguin A, Hattangadi SM, Medlock AE, Langer NB, Dailey TA, Hurst SN, Faccenda D, Wiwczar JM, Heggers SK, Vogin G, Chen W, Chen C, Campagna DR, Brugnara C, Zhou Y, Ebert BL, Danial NN, Fleming MD, Ward DM, Campanella M, Dailey HA, Kaplan J, Paw BH. Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts. Nature. 2012 Nov 22; 491(7425):608-12.
  63. Bear JR, McKay P, Nanos G, Fleming M, Rich N. Vascular injury and concomitant long-bone fracture in war wounds. J Vasc Surg. 2012 Dec; 56(6):1795-8.
  64. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27; 367(13):1187-97.
  65. Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol. 2013 Jan 24; 8:1-20.
  66. Schmidt PJ, Fleming MD. Transgenic HFE-dependent induction of hepcidin in mice does not require transferrin receptor-2. Am J Hematol. 2012 Jun; 87(6):588-95.
  67. Hartnell N, MacKinnon N, Sketris I, Fleming M. Identifying, understanding and overcoming barriers to medication error reporting in hospitals: a focus group study. BMJ Qual Saf. 2012 May; 21(5):361-8.
  68. Bartnikas TB, Parker CC, Cheng R, Campagna DR, Lim JE, Palmer AA, Fleming MD. QTLs for murine red blood cell parameters in LG/J and SM/J F(2) and advanced intercross lines. Mamm Genome. 2012 Jun; 23(5-6):356-66.
  69. Bartnikas TB, Fleming MD, Schmidt PJ. Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advances. Biochim Biophys Acta. 2012 Sep; 1823(9):1444-50.
  70. Bartnikas TB, Fleming MD. Hemojuvelin is essential for transferrin-dependent and transferrin-independent hepcidin expression in mice. Haematologica. 2012 Feb; 97(2):189-92.
  71. Anderson DS, Kirchner M, Kellogg M, Kalish LA, Jeong JY, Vanasse G, Berliner N, Fleming MD, Steen H. Design and validation of a high-throughput matrix-assisted laser desorption ionization time-of-flight mass spectrometry method for quantification of hepcidin in human plasma. Anal Chem. 2011 Nov 1; 83(21):8357-62.
  72. Vanasse GJ, Jeong JY, Tate J, Bathulapalli H, Anderson D, Steen H, Fleming M, Mattocks K, Telenti A, Fellay J, Justice AC, Berliner N. A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood. 2011 Nov 17; 118(20):5401-8.
  73. Steinbicker AU, Bartnikas TB, Lohmeyer LK, Leyton P, Mayeur C, Kao SM, Pappas AE, Peterson RT, Bloch DB, Yu PB, Fleming MD, Bloch KD. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011 Oct 13; 118(15):4224-30.
  74. Sironen A, Kotaja N, Mulhern H, Wyatt TA, Sisson JH, Pavlik JA, Miiluniemi M, Fleming MD, Lee L. Loss of SPEF2 function in mice results in spermatogenesis defects and primary ciliary dyskinesia. Biol Reprod. 2011 Oct; 85(4):690-701.
  75. Sundt TM, Fleming MD, Flemming MD, Oderich GS, Torres NE, Li Z, Lenoch J, Kalra M. Spinal cord protection during open repair of thoracic and thoracoabdominal aortic aneurysms using profound hypothermia and circulatory arrest. J Am Coll Surg. 2011 Apr; 212(4):678-83; discussion 684-5.
  76. Fleming MD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program. 2011; 2011:525-31.
  77. Bartnikas TB, Campagna DR, Antiochos B, Mulhern H, Pondarré C, Fleming MD. Characterization of mitochondrial ferritin-deficient mice. Am J Hematol. 2010 Dec; 85(12):958-60.
  78. Bartnikas TB, Fleming MD. A tincture of hepcidin cures all: the potential for hepcidin therapeutics. J Clin Invest. 2010 Dec; 120(12):4187-90.
  79. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, Jette CA, Testa JR, Neuberg DS, Langenau DM, Kutok JL, Zon LI, Traver D, Fleming MD, Kanki JP, Look AT. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell. 2010 Oct 19; 18(4):353-66.
  80. Bartnikas TB, Andrews NC, Fleming MD. Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood. 2011 Jan 13; 117(2):630-7.
  81. Wang J, Liu Y, Li Z, Du J, Ryu MJ, Taylor PR, Fleming MD, Young KH, Pitot H, Zhang J. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood. 2010 Dec 23; 116(26):5991-6002.
  82. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, Mahoney JM, Midwinter D, Vocila L, Zaks TZ. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs. 2012 Apr; 30(2):695-701.
  83. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, Dupuis J, Bouatia-Naji N, Langenberg C, Prokopenko I, Stolerman E, Sandhu MS, Heeney MM, Devaney JM, Reilly MP, Ricketts SL, Stewart AF, Voight BF, Willenborg C, Wright B, Altshuler D, Arking D, Balkau B, Barnes D, Boerwinkle E, Böhm B, Bonnefond A, Bonnycastle LL, Boomsma DI, Bornstein SR, Böttcher Y, Bumpstead S, Burnett-Miller MS, Campbell H, Cao A, Chambers J, Clark R, Collins FS, Coresh J, de Geus EJ, Dei M, Deloukas P, Döring A, Egan JM, Elosua R, Ferrucci L, Forouhi N, Fox CS, Franklin C, Franzosi MG, Gallina S, Goel A, Graessler J, Grallert H, Greinacher A, Hadley D, Hall A, Hamsten A, Hayward C, Heath S, Herder C, Homuth G, Hottenga JJ, Hunter-Merrill R, Illig T, Jackson AU, Jula A, Kleber M, Knouff CW, Kong A, Kooner J, Köttgen A, Kovacs P, Krohn K, Kühnel B, Kuusisto J, Laakso M, Lathrop M, Lecoeur C, Li M, Li M, Loos RJ, Luan J, Lyssenko V, Mägi R, Magnusson PK, Mälarstig A, Mangino M, Martínez-Larrad MT, März W, McArdle WL, McPherson R, Meisinger C, Meitinger T, Melander O, Mohlke KL, Mooser VE, Morken MA, Narisu N, Nathan DM, Nauck M, O'Donnell C, Oexle K, Olla N, Pankow JS, Payne F, Peden JF, Pedersen NL, Peltonen L, Perola M, Polasek O, Porcu E, Rader DJ, Rathmann W, Ripatti S, Rocheleau G, Roden M, Rudan I, Salomaa V, Saxena R, Schlessinger D, Schunkert H, Schwarz P, Seedorf U, Selvin E, Serrano-Ríos M, Shrader P, Silveira A, Siscovick D, Song K, Spector TD, Stefansson K, Steinthorsdottir V, Strachan DP, Strawbridge R, Stumvoll M, Surakka I, Swift AJ, Tanaka T, Teumer A, Thorleifsson G, Thorsteinsdottir U, Tönjes A, Usala G, Vitart V, Völzke H, Wallaschofski H, Waterworth DM, Watkins H, Wichmann HE, Wild SH, Willemsen G, Williams GH, Wilson JF, Winkelmann J, Wright AF, Zabena C, Zhao JH, Epstein SE, Erdmann J, Hakonarson HH, Kathiresan S, Khaw KT, Roberts R, Samani NJ, Fleming MD, Sladek R, Abecasis G, Boehnke M, Froguel P, Groop L, McCarthy MI, Kao WH, Florez JC, Uda M, Wareham NJ, Barroso I, Meigs JB. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010 Dec; 59(12):3229-39.
  84. Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60.
  85. Schmidt PJ, Andrews NC, Fleming MD. Hepcidin induction by transgenic overexpression of Hfe does not require the Hfe cytoplasmic tail, but does require hemojuvelin. Blood. 2010 Dec 16; 116(25):5679-87.
  86. Wong TE, Calicchio ML, Fleming MD, Shimamura A, Harris MH. SBDS protein expression patterns in the bone marrow. Pediatr Blood Cancer. 2010 Sep; 55(3):546-9.
  87. Moreno JA, Fleming MD, Farnell MB, Gloviczki P. Extrahepatic portal vein aneurysm. J Vasc Surg. 2011 Jul; 54(1):225-6.
  88. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, Morgan K, Tam W, Paktinat M, Okabe R, Gozo M, Einhorn W, Lane SW, Scholl C, Fröhling S, Fleming M, Ebert BL, Gilliland DG, Jaenisch R, Daley GQ. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug; 16(8):903-8.
  89. Goy A, Bernstein SH, McDonald A, Pickard MD, Shi H, Fleming MD, Bryant B, Trepicchio W, Fisher RI, Boral AL, Mulligan G. Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leuk Lymphoma. 2010 Jul; 51(7):1269-77.
  90. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16; 116(11):1919-23.
  91. Lizarraga SB, Margossian SP, Harris MH, Campagna DR, Han AP, Blevins S, Mudbhary R, Barker JE, Walsh CA, Fleming MD. Cdk5rap2 regulates centrosome function and chromosome segregation in neuronal progenitors. Development. 2010 Jun; 137(11):1907-17.
  92. Chen JH, Fleming MD, Pinkus GS, Pinkus JL, Nichols KE, Mo JQ, Perez-Atayde AR. Pathology of the liver in familial hemophagocytic lymphohistiocytosis. Am J Surg Pathol. 2010 Jun; 34(6):852-67.
  93. Finberg KE, Whittlesey RL, Fleming MD, Andrews NC. Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood. 2010 May 6; 115(18):3817-26.
  94. Freeman AL, Tornetta P, Schmidt A, Bechtold J, Ricci W, Fleming M. How much do locked screws add to the fixation of "hybrid" plate constructs in osteoporotic bone? J Orthop Trauma. 2010 Mar; 24(3):163-9.
  95. Anderson DS, Heeney MM, Roth U, Menzel C, Fleming MD, Steen H. High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine. Anal Chem. 2010 Feb 15; 82(4):1551-5.
  96. Bergmann AK, Campagna DR, McLoughlin EM, Agarwal S, Fleming MD, Bottomley SS, Neufeld EJ. Systematic molecular genetic analysis of congenital sideroblastic anemia: evidence for genetic heterogeneity and identification of novel mutations. Pediatr Blood Cancer. 2010 Feb; 54(2):273-8.
  97. Fleming MD, Stone WM, Scott P, Chapital AB, Fowl RJ, Money SR. Safety of carotid endarterectomy in patients concurrently on clopidogrel. Ann Vasc Surg. 2009 Sep-Oct; 23(5):612-5.
  98. Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg DS, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radtke I, Downing JR, Fleming MD, MacConaill LE, Amatruda JF, Gutierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT. Emi1 maintains genomic integrity during zebrafish embryogenesis and cooperates with p53 in tumor suppression. Mol Cell Biol. 2009 Nov; 29(21):5911-22.
  99. Degar BA, Fleming MD, Rollins BJ. Histiocytoses. Oncology of Infancy and Childhood (Orkin SH, Fisher D, Look AT, Lux SE, Ginsberg D, Nathan DG, editors). 2009.
  100. Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, Kellogg MD, Lachance M, Matsuoka M, Nightingale M, Rideout A, Saint-Amant L, Schmidt PJ, Orr A, Bottomley SS, Fleming MD, Ludman M, Dyack S, Fernandez CV, Samuels ME. Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet. 2009 Jun; 41(6):651-3.
  101. Zhang J, Wang J, Liu Y, Sidik H, Young KH, Lodish HF, Fleming MD. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood. 2009 Feb 5; 113(6):1304-14.
  102. Andrews NC, Ullrich C, Fleming MD. Iron metabolism and sideroblastic anemias. Nathan and Oski's Hematology of Infancy and Childhood (Orkin SH, Fisher D, Look AT, Lux SE, Ginsberg D, Nathan DG, editors). 2008.
  103. Lambe T, Simpson RJ, Dawson S, Bouriez-Jones T, Crockford TL, Lepherd M, Latunde-Dada GO, Robinson H, Raja KB, Campagna DR, Villarreal G, Ellory JC, Goodnow CC, Fleming MD, McKie AT, Cornall RJ. Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. Blood. 2009 Feb 19; 113(8):1805-8.
  104. Carpenter S, Fraser J, Fleming M, Gray R, Halyard M, Pockaj B. Optimal treatment of multiple ipsilateral primary breast cancers. Am J Surg. 2008 Oct; 196(4):530-6.
  105. Tian M, Campagna DR, Woodward LS, Justice MJ, Fleming MD. hem6: an ENU-induced recessive hypochromic microcytic anemia mutation in the mouse. Blood. 2008 Nov 15; 112(10):4308-13.
  106. Sendamarai AK, Ohgami RS, Fleming MD, Lawrence CM. Structure of the membrane proximal oxidoreductase domain of human Steap3, the dominant ferrireductase of the erythroid transferrin cycle. Proc Natl Acad Sci U S A. 2008 May 27; 105(21):7410-5.
  107. Rajagopal A, Rao AU, Amigo J, Tian M, Upadhyay SK, Hall C, Uhm S, Mathew MK, Fleming MD, Paw BH, Krause M, Hamza I. Haem homeostasis is regulated by the conserved and concerted functions of HRG-1 proteins. Nature. 2008 Jun 19; 453(7198):1127-31.
  108. Finberg KE, Heeney MM, Campagna DR, Aydinok Y, Pearson HA, Hartman KR, Mayo MM, Samuel SM, Strouse JJ, Markianos K, Andrews NC, Fleming MD. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008 May; 40(5):569-71.
  109. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008 Mar 13; 452(7184):230-3.
  110. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008 Feb 28; 451(7182):1125-9.
  111. Rodig SJ, Payne EG, Degar BA, Rollins B, Feldman AL, Jaffe ES, Androkites A, Silverman LB, Longtine JA, Kutok JL, Fleming MD, Aster JC. Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol. 2008 Feb; 83(2):116-21.
  112. Fleming MD. The regulation of hepcidin and its effects on systemic and cellular iron metabolism. Hematology Am Soc Hematol Educ Program. 2008; 151-8.
  113. Fleming M, Wentzell N. Patient safety culture improvement tool: development and guidelines for use. Healthc Q. 2008; 11(3 Spec No.):10-5.
  114. Lee L, Campagna DR, Pinkus JL, Mulhern H, Wyatt TA, Sisson JH, Pavlik JA, Pinkus GS, Fleming MD. Primary ciliary dyskinesia in mice lacking the novel ciliary protein Pcdp1. Mol Cell Biol. 2008 Feb; 28(3):949-57.
  115. Campagna DR, Custodio AO, Antiochos BB, Cirlan MV, Fleming MD. Mutations in the serum/glucocorticoid regulated kinase 3 (Sgk3) are responsible for the mouse fuzzy (fz) hair phenotype. J Invest Dermatol. 2008 Mar; 128(3):730-2.
  116. Neufeld EJ, Tubman VN, Levine JE, Campagna DR, Monahan-Earley R, Dvorak AM, Fleming MD. Response: What's in a name?. Blood. 2007; 110(7):2771.
  117. Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS. CD4+/CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol. 2007 Sep; 128(3):445-53.
  118. Wang F, Paradkar PN, Custodio AO, McVey Ward D, Fleming MD, Campagna D, Roberts KA, Boyartchuk V, Dietrich WF, Kaplan J, Andrews NC. Genetic variation in Mon1a affects protein trafficking and modifies macrophage iron loading in mice. Nat Genet. 2007 Aug; 39(8):1025-32.
  119. Tubman VN, Levine JE, Campagna DR, Monahan-Earley R, Dvorak AM, Neufeld EJ, Fleming MD. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood. 2007 Apr 15; 109(8):3297-9.
  120. Pondarre C, Campagna DR, Antiochos B, Sikorski L, Mulhern H, Fleming MD. Abcb7, the gene responsible for X-linked sideroblastic anemia with ataxia, is essential for hematopoiesis. Blood. 2007 Apr 15; 109(8):3567-9.
  121. Coughlin CM, Fleming MD, Carroll RG, Pawel BR, Hogarty MD, Shan X, Vance BA, Cohen JN, Jairaj S, Lord EM, Wexler MH, Danet-Desnoyers GA, Pinkus JL, Pinkus GS, Maris JM, Grupp SA, Vonderheide RH. Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma. J Clin Oncol. 2006 Dec 20; 24(36):5725-34.
  122. Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, St Lawrence JS, Thiede H, Handsfield HH. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006 Oct 3; 20(15):1961-8.
  123. Fleming MD, Benca RM, Behan M. Retinal projections to the subcortical visual system in congenic albino and pigmented rats. Neuroscience. 2006 Dec; 143(3):895-904.
  124. Lee L, DeBono CA, Campagna DR, Young DC, Moody DB, Fleming MD. Loss of the acyl-CoA binding protein (Acbp) results in fatty acid metabolism abnormalities in mouse hair and skin. J Invest Dermatol. 2007 Jan; 127(1):16-23.
  125. Murphy AL, Fleming M, Martin-Misener R, Sketris IS, MacCara M, Gass D. Drug information resources used by nurse practitioners and collaborating physicians at the point of care in Nova Scotia, Canada: a survey and review of the literature. BMC Nurs. 2006; 5:5.
  126. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006 Aug 15; 108(4):1388-94.
  127. Pondarré C, Antiochos BB, Campagna DR, Clarke SL, Greer EL, Deck KM, McDonald A, Han AP, Medlock A, Kutok JL, Anderson SA, Eisenstein RS, Fleming MD. The mitochondrial ATP-binding cassette transporter Abcb7 is essential in mice and participates in cytosolic iron-sulfur cluster biogenesis. Hum Mol Genet. 2006 Mar 15; 15(6):953-64.
  128. Clarke SL, Vasanthakumar A, Anderson SA, Pondarré C, Koh CM, Deck KM, Pitula JS, Epstein CJ, Fleming MD, Eisenstein RS. Iron-responsive degradation of iron-regulatory protein 1 does not require the Fe-S cluster. EMBO J. 2006 Feb 8; 25(3):544-53.
  129. Ghaffari S, Kitidis C, Zhao W, Marinkovic D, Fleming MD, Luo B, Marszalek J, Lodish HF. AKT induces erythroid-cell maturation of JAK2-deficient fetal liver progenitor cells and is required for Epo regulation of erythroid-cell differentiation. Blood. 2006 Mar 1; 107(5):1888-91.
  130. Jacobs M, Hayakawa K, Swenson L, Bellon S, Fleming M, Taslimi P, Doran J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006 Jan 6; 281(1):260-8.
  131. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE, Fleming MD. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005 Nov; 37(11):1264-9.
  132. Lim JE, Jin O, Bennett C, Morgan K, Wang F, Trenor CC, Fleming MD, Andrews NC. A mutation in Sec15l1 causes anemia in hemoglobin deficit (hbd) mice. Nat Genet. 2005 Nov; 37(11):1270-3.
  133. Zhao W, Kitidis C, Fleming MD, Lodish HF, Ghaffari S. Erythropoietin stimulates phosphorylation and activation of GATA-1 via the PI3-kinase/AKT signaling pathway. Blood. 2006 Feb 1; 107(3):907-15.
  134. Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. J Clin Invest. 2005 Aug; 115(8):2187-91.
  135. Ohgami RS, Campagna DR, Antiochos B, Wood EB, Sharp JJ, Barker JE, Fleming MD. nm1054: a spontaneous, recessive, hypochromic, microcytic anemia mutation in the mouse. Blood. 2005 Nov 15; 106(10):3625-31.
  136. Gunshin H, Starr CN, Direnzo C, Fleming MD, Jin J, Greer EL, Sellers VM, Galica SM, Andrews NC. Cybrd1 (duodenal cytochrome b) is not necessary for dietary iron absorption in mice. Blood. 2005 Oct 15; 106(8):2879-83.
  137. Han AP, Fleming MD, Chen JJ. Heme-regulated eIF2alpha kinase modifies the phenotypic severity of murine models of erythropoietic protoporphyria and beta-thalassemia. J Clin Invest. 2005 Jun; 115(6):1562-70.
  138. De Franceschi L, Rivera A, Fleming MD, Honczarenko M, Peters LL, Gascard P, Mohandas N, Brugnara C. Evidence for a protective role of the Gardos channel against hemolysis in murine spherocytosis. Blood. 2005 Aug 15; 106(4):1454-9.
  139. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
  140. Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M, Saxena K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem. 2005 Apr 8; 280(14):13728-34.
  141. Fleming M. Patient safety culture measurement and improvement: a "how to" guide. Healthc Q. 2005; 8 Spec No:14-9.
  142. de Franceschi L, Turrini F, Honczarenko M, Ayi K, Rivera A, Fleming MD, Law T, Mannu F, Kuypers FA, Bast A, van der Vijgh WJ, Brugnara C. In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia. Haematologica. 2004 Nov; 89(11):1287-98.
  143. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J. 2004 Sep 15; 23(18):3689-99.
  144. Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Blood. 2004 Oct 15; 104(8):2565-73.
  145. Huang FW, Rubio-Aliaga I, Kushner JP, Andrews NC, Fleming MD. Identification of a novel mutation (C321X) in HJV. Blood. 2004 Oct 1; 104(7):2176-7.
  146. Fleming JC, Tartaglini E, Kawatsuji R, Yao D, Fujiwara Y, Bednarski JJ, Fleming MD, Neufeld EJ. Male infertility and thiamine-dependent erythroid hypoplasia in mice lacking thiamine transporter Slc19a2. Mol Genet Metab. 2003 Sep-Oct; 80(1-2):234-41.
  147. Fleming MD, Pinkus JL, Fournier MV, Alexander SW, Tam C, Loda M, Sallan SE, Nichols KE, Carpentieri DF, Pinkus GS, Rollins BJ. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003 Apr 1; 101(7):2473-5.
  148. Fleming MD, Kutok JL, and Skarin AT. Examination of the Bone marrow. Blood: Principles and Practice of Hematology. 2003; 59-79.
  149. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell. 2002 Nov; 2(5):415-25.
  150. Fleming MD. The genetics of inherited sideroblastic anemias. Semin Hematol. 2002 Oct; 39(4):270-81.
  151. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming MD, Zimonjic DB, Popescu NC, and Weinberg RA. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. . Proc Natl Acad Sci USA. 2002; 99(20):12606-12611.
  152. Stewart SA, Hahn WC, O'Connor BF, Banner EN, Lundberg AS, Modha P, Mizuno H, Brooks MW, Fleming M, Zimonjic DB, Popescu NC, Weinberg RA. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A. 2002 Oct 1; 99(20):12606-11.
  153. Lundberg AS, Randell SH, Stewart SA, Elenbaas B, Hartwell KA, Brooks MW, Fleming MD, Olsen JC, Miller SW, Weinberg RA, Hahn WC. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene. 2002 Jul 4; 21(29):4577-86.
  154. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood. 2002 Nov 15; 100(10):3776-81.
  155. Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP. Lymphomas of the breast: primary and secondary involvement. Cancer. 2002 Jan 1; 94(1):6-13.
  156. Han AP, Yu C, Lu L, Fujiwara Y, Browne C, Chin G, Fleming M, Leboulch P, Orkin SH, Chen JJ. Heme-regulated eIF2alpha kinase (HRI) is required for translational regulation and survival of erythroid precursors in iron deficiency. EMBO J. 2001 Dec 3; 20(23):6909-18.
  157. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001 Dec 1; 98(12):3261-73.
  158. Ghaffari S, Kitidis C, Fleming MD, Neubauer H, Pfeffer K, Lodish HF. Erythropoiesis in the absence of janus-kinase 2: BCR-ABL induces red cell formation in JAK2(-/-) hematopoietic progenitors. Blood. 2001 Nov 15; 98(10):2948-57.
  159. Fleming JC, Steinkamp MP, Kawatsuji R, Tartaglini E, Pinkus JL, Pinkus GS, Fleming MD, Neufeld EJ. Characterization of a murine high-affinity thiamine transporter, Slc19a2. Mol Genet Metab. 2001 Sep-Oct; 74(1-2):273-80.
  160. Bennett CM, Kanki JP, Rhodes J, Liu TX, Paw BH, Kieran MW, Langenau DM, Delahaye-Brown A, Zon LI, Fleming MD, Look AT. Myelopoiesis in the zebrafish, Danio rerio. Blood. 2001 Aug 1; 98(3):643-51.
  161. Washington RL, Bernhardt DT, Gomez J, Johnson MD, Martin TJ, Rowland TW, Small E, LeBlanc C, Krein C, Malina R, Young JC, Reed FE, Anderson S, Bolduc S, Bar-Or O, Newland H, Taras HL, Cimino DA, McGrath JW, Murray RD, Yankus WA, Young TL, Fleming M, Glendon M, Harrison-Jones L, Newberry JL, Pattishall E, Vernon M, Wolfe L, Li S. Organized sports for children and preadolescents. Pediatrics. 2001 Jun; 107(6):1459-62.
  162. Kraus MD, Fleming MD, Vonderheide RH. The spleen as a diagnostic specimen: a review of 10 years' experience at two tertiary care institutions. Cancer. 2001 Jun 1; 91(11):2001-9.
  163. Fleming MD, Campagna DR, Haslett JN, Trenor CC, Andrews NC. A mutation in a mitochondrial transmembrane protein is responsible for the pleiotropic hematological and skeletal phenotype of flexed-tail (f/f) mice. Genes Dev. 2001 Mar 15; 15(6):652-7.
  164. Canonne-Hergaux F, Levy JE, Fleming MD, Montross LK, Andrews NC, Gros P. Expression of the DMT1 (NRAMP2/DCT1) iron transporter in mice with genetic iron overload disorders. Blood. 2001 Feb 15; 97(4):1138-40.
  165. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 2001 Jan 1; 15(1):50-65.
  166. Fleming MD and Andrews NC. The liver and iron. The Liver Biology and Pathobiology (Arias I, Boyer JL, Fausto N, Jakoby WB, Schachter D, and Shafritz DA, editors). 2001; 345-359.
  167. Canonne-Hergaux F, Fleming MD, Levy JE, Gauthier S, Ralph T, Picard V, Andrews NC, Gros P. The Nramp2/DMT1 iron transporter is induced in the duodenum of microcytic anemia mk mice but is not properly targeted to the intestinal brush border. Blood. 2000 Dec 1; 96(12):3964-70.
  168. Isaacson JH, Fleming M, Kraus M, Kahn R, Mundt M. A national survey of training in substance use disorders in residency programs. J Stud Alcohol. 2000 Nov; 61(6):912-5.
  169. Trenor CC, Campagna DR, Sellers VM, Andrews NC, Fleming MD. The molecular defect in hypotransferrinemic mice. Blood. 2000 Aug 1; 96(3):1113-8.
  170. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature. 2000 Feb 17; 403(6771):776-81.
  171. Andrews NC, Fleming MD. Commentary on: ferrokinetics in the syndrome of familial hypoferremic microcytic anemia with iron malabsorption. J Pediatr Hematol Oncol. 1999 Sep-Oct; 21(5):353-5.
  172. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood. 1999 Jul 1; 94(1):9-11.
  173. Andrews NC, Fleming MD, Gunshin H. Iron transport across biologic membranes. Nutr Rev. 1999 Apr; 57(4):114-23.
  174. Andrews NC, Fleming MD, Levy JE. Molecular insights into mechanisms of iron transport. Curr Opin Hematol. 1999 Mar; 6(2):61-4.
  175. Andrews NC and Fleming MD. Iron and erythropoiesis: Lessons from anemic mice. Molecular Biology of Hematopoiesis. 1999; 6:363-370.
  176. Andrews NC and Fleming MD. Ferrokinetics in the syndrome of familial hypoferremic microcytic anemia with iron malabsorption [commentary]. J. Ped. Hem. /Onc. 1999; 21(5):354-356.
  177. Fleming MD, Andrews NC. Mammalian iron transport: an unexpected link between metal homeostasis and host defense. J Lab Clin Med. 1998 Dec; 132(6):464-8.
  178. Kraus MD, Bartlett NL, Fleming MD, Dorfman DM. Splenic pathology in myelodysplasia: a report of 13 cases with clinical correlation. Am J Surg Pathol. 1998 Oct; 22(10):1255-66.
  179. Su MA, Trenor CC, Fleming JC, Fleming MD, Andrews NC. The G185R mutation disrupts function of the iron transporter Nramp2. Blood. 1998 Sep 15; 92(6):2157-63.
  180. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998 Sep; 2(3):305-16.
  181. Fleming MD. Hepatic iron overload in the age of hereditary hemochromatosis mutation analysis. Am J Clin Pathol. 1998 May; 109(5):505-7.
  182. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci U S A. 1998 Feb 3; 95(3):1148-53.
  183. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, and Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. . Proc Natl Acad Sci USA. 1998; 95(3):1148-1153.
  184. Fleming MD, Shahsafaei A, and Dorfman DM. Absence of dendritic reticulum cell staining is helpful for distinguishing T-cell rish B-cell lymphoma from lymphocyte predominance Hodgkin's Disease. Applied Immunochemistry. 1998; 6:16-22.
  185. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet. 1997 Aug; 16(4):383-6.
  186. Vonderheide RH, Fleming MD, Carter G, Singer S, Demetri G. Angiosarcoma. J Clin Oncol. 1997 Apr; 15(4):1708-9.
  187. Guinee D, Fleming M, Hayashi T, Woodward M, Zhang J, Walls J, Koss M, Ferrans V, Travis W. Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. Am J Pathol. 1996 Aug; 149(2):531-8.
  188. Parsons SK, Fleming MD, Nathan DG, and Andrews NC. Iron deficiency anemia associated with an error of iron metabolism in two siblings: A thirty year follow up. Hematology. 1996; 1:65-73.
  189. Fleming ID, Amonette R, Monaghan T, Fleming MD. Principles of management of basal and squamous cell carcinoma of the skin. Cancer. 1995 Jan 15; 75(2 Suppl):699-704.
  190. Fleming ID, Fleming MD. Breast cancer in elderly women. Cancer. 1994 Oct 1; 74(7 Suppl):2160-4.
  191. Fleming, MD. Dominant negative mutants of the transcription factor mXBP-1. 1993.
  192. Ivashkiv LB, Fleming MD, Glimcher LH. Dominant negative mutants of transcription factor mXBP (CRE-BP1, ATF-2). New Biol. 1992 Apr; 4(4):360-8.
  193. Fish S, Fleming M, Sharon J, Manser T. Different epitope structures select distinct mutant forms of an antibody variable region for expression during the immune response. J Exp Med. 1991 Mar 1; 173(3):665-72.
  194. Fleming, MD. Studies on the 6-Aminopenicillanic acid, acyl-coenzyme A acyltransferase from P. chrysogenum and A. nidulans. 1991.
  195. Tobin MB, Fleming MD, Skatrud PL, Miller JR. Molecular characterization of the acyl-coenzyme A:isopenicillin N acyltransferase gene (penDE) from Penicillium chrysogenum and Aspergillus nidulans and activity of recombinant enzyme in Escherichia coli. J Bacteriol. 1990 Oct; 172(10):5908-14.
  196. Tempst P, Link AJ, Riviere LR, Fleming M, Elicone C. Internal sequence analysis of proteins separated on polyacrylamide gels at the submicrogram level: improved methods, applications and gene cloning strategies. Electrophoresis. 1990 Jul; 11(7):537-53.
  197. Whiteman PA, Abraham EP, Baldwin JE, Fleming MD, Schofield CJ, Sutherland JD, Willis AC. Acyl coenzyme A: 6-aminopenicillanic acid acyltransferase from Penicillium chrysogenum and Aspergillus nidulans. FEBS Lett. 1990 Mar 26; 262(2):342-4.
  198. Fish S, Zenowich E, Fleming M, Manser T. Molecular analysis of original antigenic sin. I. Clonal selection, somatic mutation, and isotype switching during a memory B cell response. J Exp Med. 1989 Oct 1; 170(4):1191-209.
  199. Fleming M, Cohen D, Salt P, Robinson L, Spitz J. The use of an animal drawing test in the assessment and disposition of transsexualism. J Clin Psychol. 1982 Apr; 38(2):420-4.
  200. Fleming M, Cohen D, Salt P, Jones D, Jenkins S. A study of pre- and postsurgical transsexuals: MMPI characteristics. Arch Sex Behav. 1981 Apr; 10(2):161-70.
To schedule an appointment: Call 617-919-2664


We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944